Melanoma News and Research

Latest Melanoma News and Research

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

The rapidly growing field of nanotechnology and its future use in cosmetic products holds both enormous potential and potential concern for consumers. Currently, major cosmetic manufacturers have imposed a voluntary ban on the use of nanoparticles in products while they await a ruling from the Food and Drug Administration regarding the safety of this technology.

5 Mar 2010

Latest diagnostic tools play crucial role in aiding dermatologists to spot melanomas at earlier

According to estimates from the American Cancer Society, melanoma, the most serious form of skin cancer, was responsible for an estimated 8,650 deaths in the United States in 2009. Of growing concern among dermatologists is the fact that melanoma is now the most common form of cancer for young adults 25-29 years old and the second most common cancer in adolescents and young adults 15-29 years old.

5 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. Celldex reported a net loss of $13.5 million, or $0.43 per share, for the fourth quarter of 2009 compared to a net loss of $7.5 million, or $0.47 per share, for the fourth quarter of 2008.

4 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

Ichor, Profectus announce agreement for clinical development of DNA vaccine programs

Ichor Medical Systems (Ichor) and Profectus Biosciences (Profectus) announced today that they have entered into a long-term development, license, and supply Agreement providing Profectus with commercial access to Ichor’s TriGrid™ Delivery System (TriGrid™) for the clinical development of its DNA vaccine programs, with an option for Ichor to co-develop.

3 Mar 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

National Cancer Institute awards PDS Biotechnology $1.28M phase 2 SBIR contract

PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health. The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in 2010.

2 Mar 2010

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.

2 Mar 2010

AADA: U.S. Congress fails to approve legislation preventing 21% cut in payments for physicians

The American Academy of Dermatology Association is disappointed that the United States Congress has failed to approve legislation preventing the implementation of a 21 percent cut in payments for physicians who treat Medicare patients.

2 Mar 2010

Prevention of 21% cuts in Medicare payments to physicians: Congress fails to approve, AADA disappointed

The American Academy of Dermatology Association (AADA) is disappointed that the United States Congress has failed to approve legislation preventing the implementation of a 21 percent cut in payments for physicians who treat Medicare patients.

2 Mar 2010

Study compares advertising tactics between indoor tanning and tobacco industries to market unhealthy products

While the proven negative health consequences of smoking and tanning are undeniable, tobacco and indoor tanning advertisers would like consumers to think otherwise. In fact, a new study comparing the tactics used in advertising tobacco and indoor tanning products found several similarities in how these two industries market unhealthy products.

1 Mar 2010

Researchers develop noninvasive infrared scanning system to diagnose melanomas

Johns Hopkins researchers have developed a noninvasive infrared scanning system to help doctors determine whether pigmented skin growths are benign moles or melanoma, a lethal form of cancer.

27 Feb 2010

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.

27 Feb 2010

Genta initiates new dose-ranging study of tesetaxel drug

Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

26 Feb 2010

NeoGenomics' fourth-quarter revenue up 32%

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter 2009 and fiscal year ended December 31, 2009.

25 Feb 2010

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.

25 Feb 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

AutoGenomics launches expanded test panel to detect 17 B-RAF mutations

AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has launched an expanded test panel to detect 17 B-RAF mutations for research use to enhance the understanding of B-RAF mutations.

24 Feb 2010

Researchers study how laser-induced ultrasound could help identify the stage of melanoma

Knowing the stage of a patient's melanoma is important when choosing the best course of treatment. When the cancer has progressed to the lymph nodes, a more aggressive treatment is needed. Examining an entire lymph node for cancer takes much effort and time; a new technique might help make the process more efficient.

24 Feb 2010

Melanoma News and Research

Latest Melanoma News and Research

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

Latest diagnostic tools play crucial role in aiding dermatologists to spot melanomas at earlier

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Ichor, Profectus announce agreement for clinical development of DNA vaccine programs

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

National Cancer Institute awards PDS Biotechnology $1.28M phase 2 SBIR contract

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

AADA: U.S. Congress fails to approve legislation preventing 21% cut in payments for physicians

Prevention of 21% cuts in Medicare payments to physicians: Congress fails to approve, AADA disappointed

Study compares advertising tactics between indoor tanning and tobacco industries to market unhealthy products

Researchers develop noninvasive infrared scanning system to diagnose melanomas

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Genta initiates new dose-ranging study of tesetaxel drug

NeoGenomics' fourth-quarter revenue up 32%

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

EpiCept provides business update and fourth-quarter financial highlights

AutoGenomics launches expanded test panel to detect 17 B-RAF mutations

Researchers study how laser-induced ultrasound could help identify the stage of melanoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Melanoma News and Research

Latest Melanoma News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in